More importantly, numerous selective PPARγ agonists, also termed as selective PPARγ modulators (SPPARγMs), are being generated and some of them are under the clinical trials for the treatment of T2DM [12, 21]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.